Encouraged by the effective in vivo delivery of mCD19 and motivated by the limited anti-tumor efficacy of the oncolytic virus as a monotherapy, we finally examined whether mCD19 CAR T cells could be redirected to engage with B16 cells infected with mCD19 VV in vivo. Here, CXADR is linked to neoplasm.